Search Results - "Olsnes, Astrid Marta"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells by Bruserud, Oystein, Ryningen, Anita, Olsnes, Astrid Marta, Stordrange, Laila, Oyan, Anne Margrete, Kalland, Karl Henning, Gjertsen, Bjorn Tore

    Published in Haematologica (Roma) (01-03-2007)
    “…From the Division for Hematology, Department of Medicine, Haukeland University Hospital and The University of Bergen, Bergen, Norway (OB, AR, AMartO, BTG);…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5

    T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC) by Olsnes, Astrid Marta, Motorin, Dmitri, Ryningen, Anita, Zaritskey, Andrey Y, Bruserud, Øystein

    Published in Cancer Immunology, Immunotherapy (01-07-2006)
    “…T cell targeting immunotherapy is now considered in acute myelogenous leukemia (AML), and local recruitment of antileukemic T cells to the AML microcompartment…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors by Olsnes, Astrid Marta, Ersvaer, Elisabeth, Ryningen, Anita, Bruserud, Oystein

    Published in Hematology (Luxembourg) (01-12-2008)
    “…Normal T cells can mediate antileukemic reactivity after allogeneic stem cell transplantation and T cell targeting immunotherapy is now considered for patients…”
    Get more information
    Journal Article
  8. 8

    Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia by Reikvam, Håkon, Olsnes, Astrid Marta, Gjertsen, Bjørn Tore, Ersvar, Elisabeth, Bruserud, Øystein

    Published in Critical reviews in oncogenesis (2009)
    “…Acute myeloid leukemia (AML) is an aggressive malignancy with only 40%-50% long-term survival even for younger patients who can receive the most aggressive…”
    Get more information
    Journal Article
  9. 9
  10. 10